Jakafi is an anti-diabetic drug owned by Incyte Corp. This drug contains the active ingredient ruxolitinib phosphate. Jakafi was first authorized for market use on November 16, 2011 and it comes in a tablet that is ingested orally.
The generics of Jakafi are supposed to be released after March 22, 2029. This is due to the patents held by the drug with the last patent expiring on the aforementioned date.
Jakafi has numerous uses primarily revolving around the treatment of chronic graft-versus-host disease (cgvhd) after one or two failed attempts of systemic therapy. Additionally, it's also used in the treatment of steroid-refractory acute graft-versus-host disease (agvhd). Moreover, Jakafi also proves effective in the treatment of polycythemia vera (pv) when patients don't respond adequately or show intolerance towards hydroxyurea. Jakafi also notably inhibits janus associated kinases (jaks) jak1 and/or jak2. Finally, Jakafi can also be used to treat intermediate or high-risk myelofibrosis (mf), which could be primary mf, post-polycythemia vera mf or post-essential thrombocythemia mf.
Jakafi is protected by 16 patents, all of which are still in effect with the last one due to expire on March 22, 2029. As a result, the generics of Jakafi are expected to become available after this date. Below are the details of the patent: